AXSM — Axsome Therapeutics Share News
0.000.00%
Last trade - 00:00- $7.51bn
- $7.40bn
- $638.50m
Axsome Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Axsome Therapeutics, Wayfair, IDEXX Laboratories
Axsome Therapeutics rises after Q2 revenue beat
Axsome Therapeutics's Q2 revenue rises 72% to $150 mln
Brief: Axsome Therapeutics Announces Availability Of Symbravo® For The Acute Treatment Of Migraine
U.S. STOCKS ON THE MOVE-Copper miners, Chip Stocks, EchoStar
U.S. STOCKS ON THE MOVE- Metsera, Cameco, Circle Internet
U.S. STOCKS ON THE MOVE-Oklo, Tesla, Plug Power
Axsome slips as FDA rejects fibromyalgia drug application, forcing new trial
Brief: Axsome Therapeutics Provides Update On The New Drug Application For Axs-14 For Fibromyalgia
Brief: Axsome Therapeutics Settles Sunosi Patent Litigation With Hetero Labs
Brief: Axsome Therapeutics Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone
Axsome Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Shake Shack, SatixFy, Enova
U.S. STOCKS ON THE MOVE-Shake Shack, SatixFy, Enova
Axsome falls on depression drug's trial setback
Axsome falls on depression drug's trial setback
Axsome to narrow focus of depression drug trial after limited success in initial run (updated)
Axsome's depression treatment fails to meet main goal of late-stage study